U.S., March 7 -- ClinicalTrials.gov registry received information related to the study (NCT06861621) titled 'STRucturation of Transcript Analysis of Genes Involved in Hereditary Cancers' on Feb. 19.
Brief Summary: Molecular diagnosis using high throughput sequencing has become an essential part of oncogenetic care, making it possible to identify people at risk, to guide surveillance, and to direct preventive surgery and treatment. The quality of this 'precision' care depends on the quality of the interpretation of the genomic variants identified. To be usable in oncogenetics, a genomic variant must be correctly interpreted: pathogenic, benign or of uncertain significance (VSI). The impact of these DNA variants (VSI) on RNA is particularly ...